About

About BPM Summit

This year marks the 15th anniversary of the completion of the Human Genome Project. In the decade and a half that has passed since, the genomic revolution has spurred an immeasurable level of excitement and support surrounding the promise of personalized medicine, setting high expectations for a new era of health care and rapidly transforming the field into a multi-billion dollar industry. While realizing the enormous potential of personalized medicine has turned out to be neither quick nor easy, recent scientific and technological progress has been impressive, pointing to a possible tipping point.
The 5th Annual Business of Personalized Medicine Summit will bring together top executives from across multiple stakeholder perspectives for a look at the state of the industry past, present, and future. Through a series of thought-provoking discussions, the 2018 Summit will:
  • Explore solutions to the obstacles and limitations that have kept us from realizing the full promise of personalized medicine to date, as well as emerging challenges we must overcome to continue advancing medicine and the marketplace
  • Celebrate the extraordinary achievements in innovation and collaboration that have led us to where we are now while looking ahead to promising new advances underway
  • Examine the complexities, trends, and opportunities of an evolving personalized medicine landscape driven by the convergence of science and technology, including implications for the future of business and policy in the field
Join us in San Francisco on Thursday, May 10, for this can’t-miss day of networking and thought leadership.
 

Who Should Attend?

  • Business, legal, and health care professionals interested in industry leaders' real-world experience on the current state of personalized medicine and where growth and opportunity exist
  • Business, legal, and health care professionals interested in discussions regarding the regulatory framework for diagnostics and targeted therapies
  • Executives and entrepreneurs interested in hearing diverse perspectives on both the development and delivery of personalized medicine therapies
  • Payors interested in the current status and future possibilities regarding reimbursement of personalized medicine technologies
  • Corporate counsel in life sciences and health care provider organizations
  • Health care professionals working in the field of personalized medicine
  • Health care and life sciences investors
  • Researchers and academic personnel
  • Non-profit organizations